



#### **How to Receive CME and MOC Points**

LIVE VIRTUAL GRAND ROUNDS WEBINAR

ACG will send a link to a CME & MOC evaluation to all attendees on the live webinar.

ABIM Board Certified physicians need to complete their MOC activities by <u>December 31</u>, <u>2021</u> in order for the MOC points to count toward any MOC requirements that are due by the end of the year. No MOC credit may be awarded after <u>March 1</u>, <u>2022</u> for this activity.

3



universe.gi.org

## **MOC QUESTION**

If you plan to claim MOC Points for this activity, you will be asked to: Please list specific changes you will make in your practice as a result of the information you received from this activity.

Include specific strategies or changes that you plan to implement.

THESE ANSWERS WILL BE REVIEWED.



ACG) Virtual Grand Rounds universe.gi.org **ACG VIRTUAL GRAND ROUNDS** Allyship and Action: In Solidarity Against Anti-Asian Racism **MONDAY, MAY 10, 8-9:30 PM EDT** Moderators **Panel** Samir A. Shah, MD, FACG William D. Chey, MD, FACG Immanuel K. H. Ho, MD, FACG Monica Nandwani, NP Linda Anh B. Nguyen, MD Speaker Calvin Q. Pan, MD, FACG Stella S. Yi, PhD, MPH Chung Sang Tse, MD Register: gi.org/ACGVGR #Glhomeschooling



#### **Disclosures:**



Speaker:
Carol E. Semrad, MD, FACG
Dr. Semrad, faculty for this educational event, has no relevant financial relationship(s) with ineligible companies to disclose.



Moderator: Dejan Micic, MD Advisory Board: Takeda Pharmaceuticals

\*All of the relevant financial relationships listed for these individuals have been mitigated.

7



universe.gi.org

## **Small Bowel Bleeding**



Carol E. Semrad, MD, FACG Professor of Medicine Director, Small Bowel Disease and Nutrition

(AG) Virtual Grand Rounds

universe.gi.org

## **Small Bowel Bleeding**

- 5% of GI bleeders
- Most difficult and costly bleeders


10




universe.gi.org

## Small Bowel Bleeding Outline

- Terminology
- Small Bowel Endoscopic and Imaging Modalities
- Making a Diagnosis/Therapy





## AGG Virtual Grand Rounds

universe.gi.org

universe.gi.org

## **Small Bowel Bleeding Imaging Modalities**

Test	Diagnostic Yield	
Small Bowel Barium	5%	
Push Enteroscopy	30%	
Multi-Phase CT Enterography	48%	
Capsule Endoscopy	38-83%	
Device-Assist Enteroscopy	51-80%	
Intraoperative Enteroscopy	75-90%	

Triester et al. Am J Gastroenterol 2005;100:2407 Huprich et al. Radiology 2011:260:744 Gerson et al. ACG Clinical Guideline, Am J Gastroenterol 2015;110:1265

14

Virtual Grand Rounds

**Small Bowel Capsule Endoscopy** 

What is it good for?





Yield highest


- When performed within first 24-72 hrs in overt bleeding<sup>1</sup>
- Guides therapeutic approach
  - Lesion < 60% SB transit time, upper DAE approach<sup>2</sup>
- Yield of repeat capsule ~ 40% when<sup>3</sup>
  - Change from occult to overt bleed
  - Hemoglobin drop > 4 g/dl

<sup>1</sup>Rondonotti et al. ESGE guidelines. Endoscopy 2018;50:423. <sup>2</sup>Li et al. Endoscopy 2009;41:762

<sup>3</sup>Viazis et al. Gastrointest Endosc 2009;69:850







(AG) Virtual Grand Rounds

# Comparison of Enteroscopy Devices Double vs. Single Balloon vs. Spiral

- Diagnostic yields similar 50-80%
- Summary of small studies

DBE - deepest insertion

SBE - easiest set-up

Spiral - fastest

- Complications similar
  - Perforation, pancreatitis (0.3%)
- All get deeper than push enteroscopy
  - 80 cm vs 230 cm depth
  - 44% vs 62% diagnostic yield

May et al. Am J Gastro 2006;101:2015 May et al. Am J Gastro 2010;105:575 Morgan et al. Gastro Endosc 2010;72:992 Domagk. Endoscopy 2011;43:472 Takano. Gastro Endosc 2011;73:734

Messer. Gastro Endosc 2013;77:241

18



#### **Device-Assist Enteroscopy**

universe.gi.org

universe.gi.org

#### **Advantages**

- · Allows therapy
- Best yield when performed within 24-72 hrs of overt bleed<sup>1,2</sup>
- · Sampling, lesion marking
  - Minimally invasive surgery
- Best modality for Meckel diverticulum
  - 40% false negative, adult Meckel scans

#### **Limitations**

- · Labor intensive
- · Steep Learning Curve
  - 150 cases to achieve total exam<sup>3</sup>
- Incomplete examinations

<sup>&</sup>lt;sup>1</sup> Aniwan et al. Endosc Int Open 2014;2:E90-5

<sup>&</sup>lt;sup>2</sup> Rodrigues et al. Eur J Gastroenterol Hepatol 2018;30:1304

<sup>&</sup>lt;sup>3</sup> Gross, Stark. Gastrointest Endosc 2008;67:898




#### **CT Enterography**

#### Advantages

- · Best at detecting
  - Mass lesion > 5mm size
  - Wall thickening, stenosis
- · Localization, size

#### Disadvantages








20




universe.gi.org

#### **Suspected Small Bowel Bleeding**

- · Making a diagnosis
- · What is the best initial test?







## **Important Physical Findings**

- Mucocutaneous telangiectasias
   HHT
- Hyperpigmentation lip/skin
  - Peutz Jeghers Syndrome
- Skin hemangiomas
  - Blue Rubber Bleb Nevus Syndrome
- · SEM of severe aortic stenosis
  - Anigoectasias, Heyde's Syndrome




24

(AG) Virtual Grand Rounds

universe.gi.org

#### Case


- 26 y.o. woman, 35 wks pregnant
- History of unprovoked GI bleed (melena) 2 yrs ago
  - EGD, colonoscopy, CE, Meckel scan: All negative
  - Told to have CTA if she had recurrent bleeding
- Now with recurrent overt GI bleeding (melena)
- Transfused 8 Units PRBC
- ? Best test for diagnosis
  - 40% yield on repeat CE
  - CTE/MRE






- Mother given steroid injections to mature fetal lung at 35 wks
- · Admitted to hospital for induced delivery
- Standby for emergency C section and tumor resection if GI bleeding with delivery








26




universe.gi.org

### Lessons

- · Beware unexplained overt GI bleeding in the young
- CE misses ~ 20% of small bowel mass lesions
- Retrospective review of her first CE showed debris in proximal SB
- Yield of repeat CE good when recurrent overt bleeding
- Consider CTE/MRE as the first test in young with overt bleeding





(AG) Virtual Grand Rounds

## Lesion Marking, Laparoscopic Resection

universe.gi.org

- Indication
  - Subepithelial mass lesion
  - Ulcer/stenosis
- Device-assist Enteroscopy
  - Biopsy lesion
  - Tattoo at 2 sites
- Surgical resection
  - Intracorporeal (laparoscopic, internal)
  - Extracorporeal (open, mini-lap, external)





Tapaskar et al Abstract DDW 2018 Yeh et al. Surg Endosc 2009;23:739

30



universe.gi.org

#### **Small Bowel Vascular Lesions**

- · Acquired most common
  - Angioectasias
  - Dieulafoy lesion
- Hereditary hemorrhagic telangiectasia (HHT)
  - Autosomal dominant, 1:5,000 worldwide
  - Mutations disrupt TGF- $\beta$  pathways in vascular endothelial cells
  - Epistaxis most common cause of bleeding/anemia
  - GI bleeding in 30%
  - AVMs liver, lung, brain
  - Juvenile polyposis-HHT with SMAD4 mutation<sup>1</sup>

 $^{1}$ McDonald et al. Int J Colorectal Dis 2020;35:1963




#### **Angioectasia**

universe.gi.org

- · Most common cause of SB bleeding in elderly
- · Upper SB most common site
- · Overt or occult GI bleeding
- Risk factors
  - Aortic Stenosis (Heyde syndrome)
  - Von Willebrand disease
  - Chronic renal failure
  - Left Ventricular Assist Device (LVAD)
  - Smoking
- Most common finding on CE performed for OGIB in U.S.A.

32






#### **Diagnosis Small Bowel Vascular Lesions**

- · Capsule Endoscopy
  - Best test for flat lesions
  - Least invasive, best tolerated
  - Guides therapy
- · Device-Assisted Enteroscopy
  - Invasive
  - Allows therapy
- Multiphase CT Enterography
  - Uncertain yield for vascular lesions
  - Embolization therapy in SB limited due to ischemia risk

34





#### **CASE**

- 73 y.o. with CHF S/P LVAD on warfarin
- · Recurrent overt bleeds
- Duodenal angioectasias treated in past
- · Presents with melena, EGD negative
- VCE:
  - Red blood without underlying lesion
  - Starting at 17% of SB transit time



36

#### (AG) Virtual Grand Rounds

universe.gi.org


## **Outcomes in Small Bowel Bleeding**

Study DBE	Age yrs	Bleed type	Lesions	F/U mo	Rebleed
Sun <sup>1</sup> , China N=119	42	overt > occult	AVM 30%	18	11%
Arakawa², Japan N=162	63	overt > occult	AVM 23%	18	7%
Gerson <sup>3</sup> , USA N=135	68	overt = occult	AVM 43%	30	42%
May <sup>4</sup> , Germany N=50	68	overt > occult	AVM 80%	55	41%


<sup>1</sup>Am J Gastroenterol 2006;101:2011


<sup>3</sup>Clin Gastroenterol Hepatol 2009;7:66


<sup>2</sup>Gastrointest Endosc 2009;69:866 <sup>4</sup>Endoscopy 2011;43:759



AGG Virtual Grand Rounds universe.gi.org **Medical Therapy** Agent Mechanism **Re-bleeding Side Effects** Octreotide<sup>1</sup> splanchnic flow decreased low Prospective studies vascular resistance p < 0.04 inhibits angiogenesis Thalidomide<sup>2</sup> inhibits angiogenesis decreased high PRT p < 0.001 Anti-VEGF<sup>3</sup> inhibits VEGF high case reports in HHT <sup>1</sup>Am J Gastroenterol 2007;102:254 <sup>2</sup>Gastroenterology 2011;141:1629 <sup>3</sup>Gastroenterol 2013:47:256







**CONNECT AND COLLABORATE IN GI ACG Hepatology Circle ACG & CCF IBD Circle ACG GI Circle ACG Functional GI** Connect and collaborate within GI ACG Women in GI Circle **Health and Nutrition Circle ACG's Online Professional Networking Communities** LOGIN OR SIGN-UP NOW AT: acg-gi-circle.within3.com